Literature DB >> 10979210

Neuron-specific enolase in hemophagocytic lymphohistiocytosis: a potential indicator for macrophage activation?

K Honda1, S Ohga, H Takada, A Nomura, K Ohshima, N Kinukawa, Y Mizuno, T Hara.   

Abstract

To determine the pathogenesis of hemophagocytic lymphohistiocytosis (HLH), serum levels of neuron-specific enolase (NSE) and cytokine profiles were investigated. Serum concentrations of NSE and several cytokines were measured by immunoassays, and the association was evaluated in 18 HLH patients. Serum NSE levels increased (> 10 ng/mL) in 27/29 samples (93%) during the active febrile phase, the mean level of which (35.9 ng/mL) was much higher than that during the remission phase (11.2 ng/mL) (P = .001). The peak levels of NSE in 11 patients who required cytotoxic agents were higher than those in 7 patients without chemotherapy, 64.6 +/- 49.4 and 17.9 +/- 12.9, respectively (P = .265). The NSE levels correlated positively with the levels of interferon (IFN)-gamma (Pearson's correlation coefficient [r] = 0.408, P = .044), soluble interleukin-2 receptor (sIL-2R) (r = 0.464, P = .048), lactate dehydrogenase (r = 0.830, P < .00001), aspartate aminotransferase (r = 0.531, P = .003), and ferritin (r = 0.715, P < .00001), and correlated negatively with platelet count (r = -0.422, P = .021), but not with other parameters, including tumor necrosis factor-alpha, IL-1 beta, IL-18, soluble Fas ligand and C-reactive protein. Multiple regression analysis indicated that the correlation of NSE with platelet count was independent of other correlations. Sequential NSE changes well reflected the clinical course of patients. Immunohistochemical staining revealed an appreciable number of NSE-positive histiocytes in bone marrow specimens with florid hemophagocytosis. These results suggest that the circulating NSE originated from macrophages stimulated with IFN-gamma/sIL-2R, and partly from the destruction of platelets. Serum NSE level may be a useful marker for predicting the disease progression of HLH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979210

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  9 in total

1.  Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype.

Authors:  Lixin Kan; Min Hu; William A Gomes; John A Kessler
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 2.  Overview of the IL-1 family in innate inflammation and acquired immunity.

Authors:  Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

Review 3.  Interleukin-18 and IL-18 binding protein.

Authors:  Charles A Dinarello; Daniela Novick; Soohyun Kim; Gilles Kaplanski
Journal:  Front Immunol       Date:  2013-10-08       Impact factor: 7.561

4.  Neuron-specific enolase as a novel biomarker reflecting tuberculosis activity and treatment response.

Authors:  Sung-Jin Nam; Jee-Yeong Jeong; Tae-Won Jang; Mann-Hong Jung; Bong-Kwon Chun; Hee-Jae Cha; Chul-Ho Oak
Journal:  Korean J Intern Med       Date:  2016-06-03       Impact factor: 2.884

Review 5.  Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases.

Authors:  Seung Yong Park; Yasmin Hisham; Hyun Mu Shin; Su Cheong Yeom; Soohyun Kim
Journal:  Biomedicines       Date:  2022-07-20

6.  The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome - a systematic review.

Authors:  J M Krei; H J Møller; J B Larsen
Journal:  Clin Exp Immunol       Date:  2020-11-23       Impact factor: 4.330

7.  Synchronous brain and intravascular B-cell lymphoma after remission of an adult hemophagocytic syndrome.

Authors:  Válter R Fonseca; Eduardo Espada; Ruth Geraldes; Santiago Ortiz; Rita Sousa; Dolores Lopez; Marisa Teixeira Silva; Rui Victorino
Journal:  Clin Case Rep       Date:  2016-02-16

8.  Serum enolase-2, high-sensitivity C-reactive protein, and serum cholesterol in smear-positive drug-naïve pulmonary tuberculosis.

Authors:  Suhail Ahmed Almani; Tariq Zaffar Shaikh; Haji Khan Khoharo; Ikramuddin Ujjan
Journal:  J Res Med Sci       Date:  2017-04-26       Impact factor: 1.852

Review 9.  Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.